Applied Therapeutics Inc (NASDAQ: APLT) on Tuesday, plunged -1.59% from the previous trading day ,before settling in for the closing price of $5.66. Within the past 52 weeks, APLT’s price has moved between $0.76 and $9.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 52.74%. With a float of $74.23 million, this company’s outstanding shares have now reached $84.87 million.
Let’s determine the extent of company efficiency that accounts for 25 employees.
Applied Therapeutics Inc (APLT) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Applied Therapeutics Inc is 29.89%, while institutional ownership is 56.10%. The most recent insider transaction that took place on Mar 14 ’24, was worth 1,717,108. In this transaction President and CEO of this company sold 318,573 shares at a rate of $5.39, taking the stock ownership to the 3,817,814 shares. Before that another transaction happened on Mar 14 ’24, when Company’s Chief Medical Officer sold 110,804 for $5.39, making the entire transaction worth $597,234. This insider now owns 1,031,537 shares in total.
Applied Therapeutics Inc (APLT) Earnings and Forecasts
As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.34 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.23) by -$0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.74% per share during the next fiscal year.
Applied Therapeutics Inc (NASDAQ: APLT) Trading Performance Indicators
Applied Therapeutics Inc (APLT) is currently performing well based on its current performance indicators. A quick ratio of 0.80 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.35 in one year’s time.
Technical Analysis of Applied Therapeutics Inc (APLT)
Looking closely at Applied Therapeutics Inc (NASDAQ: APLT), its last 5-days average volume was 1.0 million, which is a drop from its year-to-date volume of 2.11 million. As of the previous 9 days, the stock’s Stochastic %D was 6.15%. Additionally, its Average True Range was 0.54.
During the past 100 days, Applied Therapeutics Inc’s (APLT) raw stochastic average was set at 49.74%, which indicates a significant increase from 9.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.27% in the past 14 days, which was lower than the 145.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.33, while its 200-day Moving Average is $2.92. However, in the short run, Applied Therapeutics Inc’s stock first resistance to watch stands at $5.72. Second resistance stands at $5.88. The third major resistance level sits at $6.05. If the price goes on to break the first support level at $5.40, it is likely to go to the next support level at $5.23. Should the price break the second support level, the third support level stands at $5.07.
Applied Therapeutics Inc (NASDAQ: APLT) Key Stats
Market capitalization of the company is 589.81 million based on 105,887K outstanding shares. Right now, sales total 9,990 K and income totals -119,760 K. The company made -670 K in profit during its latest quarter, and -37,680 K in sales during its previous quarter.
